Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dow Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Dow Inc trades at $29.37 (market cap $20.64B). The key difference: Dow Inc is far larger — about 4.6× ACADIA Pharmaceuticals Inc.'s market cap, and Dow Inc pays a 4.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DOW | |
|---|---|---|
Market Cap | $4.49B | $20.64B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $41.87 |
52-Week Low | $20.06 | $20.65 |
Enterprise Value | $3.69B | $36.42B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DOW trades at $28.64, up 3.36% today, with a bearish technical signal despite recent earnings beats. The stock shows negative profitability with a net income margin of -7.24% and ROE of -17.85%, though valuation ratios like P/S of 0.5 appear modest. Cash flow trends indicate operational challenges, with 2025 operating cash flow at $1.03B down from prior years, while the company maintains a dividend payout.
Outlook remains cautious due to weak fundamentals and bearish technicals, but analyst consensus price target of $36.11 suggests 26% upside. Key risks include sustained negative margins and high debt levels, while potential catalysts hinge on cost-cutting effectiveness and market demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
